Sodium arsenite induces apoptosis and Epstein-Barr virus reactivation in lymphoblastoid cells

Biochimie

Volumn 107, Issue PB, 2014, Pages 247-256

  Zebboudj, Abderezak ^a,b   Maroui, Mohamed Ali ^b   Dutrieux, Jacques ^b   Touil Boukoffa, Chafia ^a   Bourouba, Mehdi ^a   Chelbi Alix, Mounira K ^b   Nisole, Sébastien ^b  

^a UNIVERSITY OF SCIENCES AND TECHNOLOGY HOUARI BOUMEDIENE   (Algeria)

^b Pharmacologie Toxicologie et Signalisation Cellulaire   (France)

Author keywords

Arsenic; Epstein Barr virus; Latency; LMP1; PML

Indexed keywords

ARSENIC TRIOXIDE; ARSENITE SODIUM; CASPASE; IMMEDIATE EARLY PROTEIN; IMMEDIATE EARLY PROTEIN BZLF1; LATENT MEMBRANE PROTEIN 1; PROTEIN RTA; UNCLASSIFIED DRUG; ARSENOUS ACID DERIVATIVE; AUTOANTIGEN; CELL NUCLEUS ANTIGEN; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN; NUCLEAR PROTEIN; ORGANOARSENIC DERIVATIVE; OXIDE; PML PROTEIN, HUMAN; SODIUM DERIVATIVE; SP100 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; AUTOPHAGY; BURKITT LYMPHOMA CELL LINE; CONTROLLED STUDY; DOWN REGULATION; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; NONHUMAN; PROTEIN EXPRESSION; VIROGENESIS; VIRUS REACTIVATION; WESTERN BLOTTING; BURKITT LYMPHOMA; CELL PROLIFERATION; DRUG EFFECTS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; VIROLOGY;

HUMAN HERPESVIRUS 4;

ANTIGENS, NUCLEAR; APOPTOSIS; ARSENICALS; ARSENITES; AUTOANTIGENS; AUTOPHAGY; BURKITT LYMPHOMA; CELL LINE, TUMOR; CELL PROLIFERATION; HERPESVIRUS 4, HUMAN; HUMANS; NUCLEAR PROTEINS; OXIDES; SODIUM COMPOUNDS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; VIRAL MATRIX PROTEINS;

EID: 84915737431     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2014.09.002     Document Type: Article

References (50)

1. L.S. Young, and A.B. Rickinson Epstein-Barr virus: 40 years on Nat. Rev. Cancer 4 2004 757 768
2. A.G. Eliopoulos, C.W. Dawson, G. Mosialos, J.E. Floettmann, M. Rowe, R.J. Armitage, J. Dawson, J.M. Zapata, D.J. Kerr, M.J. Wakelam, J.C. Reed, E. Kieff, and L.S. Young CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator Oncogene 13 1996 2243 2254
3. R.K. Moorthy, and D.A. Thorley-Lawson All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts J. Virol. 67 1993 1638 1646
4. D. Wang, D. Liebowitz, and E. Kieff An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells Cell 43 1985 831 840
5. K.M. Kaye, K.M. Izumi, and E. Kieff Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation Proc. Natl. Acad. Sci. U. S. A. 90 1993 9150 9154
6. B. Adler, E. Schaadt, B. Kempkes, U. Zimber-Strobl, B. Baier, and G.W. Bornkamm Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1 Proc. Natl. Acad. Sci. U. S. A. 99 2002 437 442
7. S. Prince, S. Keating, C. Fielding, P. Brennan, E. Floettmann, and M. Rowe Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms J. Virol. 77 2003 5000 5007
8. L. Zhang, L. Wu, K. Hong, and J.S. Pagano Intracellular signaling molecules activated by Epstein-Barr virus for induction of interferon regulatory factor 7 J. virol. 75 2001 12393 12401
9. J. Zhang, S.C. Das, C. Kotalik, A.K. Pattnaik, and L. Zhang The latent membrane protein 1 of Epstein-Barr virus establishes an antiviral state via induction of interferon-stimulated genes J. Biol. Chem. 279 2004 46335 46342
10. M.D. Sides, G.J. Block, B. Shan, K.C. Esteves, Z. Lin, E.K. Flemington, and J.A. Lasky Arsenic mediated disruption of promyelocytic leukemia protein nuclear bodies induces ganciclovir susceptibility in Epstein-Barr positive epithelial cells Virology 416 2011 86 97
11. C. Du, B. Wen, D. Li, Y. Lin, Y. Zheng, X. Peng, C. Hong, J. Chen, W. Lin, X. Hong, L. Xie, and M. Wu Downregulation of Epstein-Barr virus-encoded latent membrane protein-1 by arsenic trioxide in nasopharyngeal carcinoma cells Tumori 92 2006 140 148
12. M.D. Sides, M.L. Sosulski, F. Luo, Z. Lin, E.K. Flemington, and J.A. Lasky Co-treatment with arsenic trioxide and ganciclovir reduces tumor volume in a murine xenograft model of nasopharyngeal carcinoma Virol. J. 10 2013 152
13. F. El Asmi, M.A. Maroui, J. Dutrieux, D. Blondel, S. Nisole, and M.K. Chelbi-Alix Implication of PMLIV in both intrinsic and innate immunity PLoS pathog. 10 2014 e1003975
14. A.M. Ishov, A.G. Sotnikov, D. Negorev, O.V. Vladimirova, N. Neff, T. Kamitani, E.T. Yeh, J.F. Strauss 3rd, and G.G. Maul PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1 J. Cell Biol. 147 1999 221 234
15. R. Bernardi, A. Papa, and P.P. Pandolfi Regulation of apoptosis by PML and the PML-NBs Oncogene 27 2008 6299 6312
16. E. Krieghoff-Henning, and T.G. Hofmann Role of nuclear bodies in apoptosis signalling Biochim. Biophys. Acta 1783 2008 2185 2194
17. G. Jin, Y.J. Wang, and H.K. Lin Emerging cellular functions of Cytoplasmic PML Front. Oncol. 3 2013 147
18. R.D. Everett, and M.K. Chelbi-Alix PML and PML nuclear bodies: implications in antiviral defence Biochimie 89 6-7 2007 819 830
19. S. Nisole, M.A. Maroui, X.H. Mascle, M. Aubry, and M.K. Chelbi-Alix Differential roles of PML isoforms Front. Oncol. 3 2013 125
20. G.A. Dos Santos, L. Kats, and P.P. Pandolfi Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia J. Exp. Med. 210 2013 2793 2802
21. L. Ouyang, Z. Shi, S. Zhao, F.T. Wang, T.T. Zhou, B. Liu, and J.K. Bao Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis Cell. Prolif. 45 2012 487 498
22. G. Marino, M. Niso-Santano, E.H. Baehrecke, and G. Kroemer Self-consumption: the interplay of autophagy and apoptosis Nat. Rev. Mol. Cell. Biol. 15 2014 81 94
23. S.W. Ryter, K. Mizumura, and A.M. Choi The impact of autophagy on cell death modalities Int. J. Cell Biol. 2014 2014 502676
24. W. Chaabane, S.D. User, M. El-Gazzah, R. Jaksik, E. Sajjadi, J. Rzeszowska-Wolny, and M.J. Los Autophagy, apoptosis, mitoptosis and necrosis: interdependence between those pathways and effects on cancer Arch. Immunol. Ther. Exp. 61 2013 43 58
25. S.J. Ralph Arsenic-based antineoplastic drugs and their mechanisms of action Metal-based drugs 2008 2008 260146
26. Y. Kumagai, and D. Sumi Arsenic: signal transduction, transcription factor, and biotransformation involved in cellular response and toxicity Annu. Rev. Pharmacol. Toxicol. 47 2007 243 262
27. W.H. Miller Jr., H.M. Schipper, J.S. Lee, J. Singer, and S. Waxman Mechanisms of action of arsenic trioxide Cancer Res. 62 2002 3893 3903
28. J. McCafferty-Grad, N.J. Bahlis, N. Krett, T.M. Aguilar, I. Reis, K.P. Lee, and L.H. Boise Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells Mol. Cancer Ther. 2 2003 1155 1164
29. H.W. Chiu, Y.S. Ho, and Y.J. Wang Arsenic trioxide induces autophagy and apoptosis in human glioma cells in vitro and in vivo through downregulation of survivin J. Mol. Med. 89 2011 927 941
30. T. Kanzawa, Y. Kondo, H. Ito, S. Kondo, and I. Germano Induction of autophagic cell death in malignant glioma cells by arsenic trioxide Cancer Res. 63 2003 2103 2108
31. W. Qian, J. Liu, J. Jin, W. Ni, and W. Xu Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1 Leukemia Res. 31 2007 329 339
32. X. Cui, Y. Kobayashi, M. Akashi, and R. Okayasu Metabolism and the paradoxical effects of arsenic: carcinogenesis and anticancer Curr. Med. Chem. 15 2008 2293 2304
33. S. Pattingre, A. Tassa, X. Qu, R. Garuti, X.H. Liang, N. Mizushima, M. Packer, M.D. Schneider, and B. Levine Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy Cell 122 2005 927 939
34. Y. Wei, S. Pattingre, S. Sinha, M. Bassik, and B. Levine JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy Mol. Cell. 30 2008 678 688
35. E. Wirawan, L. Vande Walle, K. Kersse, S. Cornelis, S. Claerhout, I. Vanoverberghe, R. Roelandt, R. De Rycke, J. Verspurten, W. Declercq, P. Agostinis, T. Vanden Berghe, S. Lippens, and P. Vandenabeele Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria Cell Death Dis. 1 2010 e18
36. J.P. Decuypere, J.B. Parys, and G. Bultynck Regulation of the autophagic bcl-2/beclin 1 interaction Cells 1 2012 284 312
37. N. Mizushima, and T. Yoshimori How to interpret LC3 immunoblotting Autophagy 3 2007 542 545
38. M.H. Tatham, M.C. Geoffroy, L. Shen, A. Plechanovova, N. Hattersley, E.G. Jaffray, J.J. Palvimo, and R.T. Hay RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation Nat. Cell. Biol. 10 5 2008 538 546
39. J. Fullgrabe, D.J. Klionsky, and B. Joseph The return of the nucleus: transcriptional and epigenetic control of autophagy Nat. Rev. Mol. Cell. Biol. 15 2014 65 74
40. S. Polager, M. Ofir, and D. Ginsberg E2F1 regulates autophagy and the transcription of autophagy genes Oncogene 27 2008 4860 4864
41. A.M. Bolt, R.M. Douglas, and W.T. Klimecki Arsenite exposure in human lymphoblastoid cell lines induces autophagy and coordinated induction of lysosomal genes Toxicol. Lett. 199 2010 153 159
42. J. Zhu, H. Okumura, S. Ohtake, S. Nakamura, and S. Nakao The molecular mechanism of arsenic trioxide-induced apoptosis and oncosis in leukemia/lymphoma cell lines Acta Haematol. 110 2003 1 10
43. D.Y. Lee, and B. Sugden The latent membrane protein 1 oncogene modifies B-cell physiology by regulating autophagy Oncogene 27 2008 2833 2842
44. P. Bell, P.M. Lieberman, and G.G. Maul Lytic but not latent replication of Epstein-Barr virus is associated with PML and induces sequential release of nuclear domain 10 proteins J. Virol. 74 2000 11800 11810
45. S. Wang, J. Long, and C.F. Zheng The potential link between PML NBs and ICP0 in regulating lytic and latent infection of HSV-1 Protein cell. 3 2012 372 382
46. F. Dag, L. Dolken, J. Holzki, A. Drabig, A. Weingartner, J. Schwerk, S. Lienenklaus, I. Conte, R. Geffers, C. Davenport, U. Rand, M. Koster, S. Weiss, B. Adler, D. Wirth, M. Messerle, H. Hauser, and L. Cicin-Sain Reversible silencing of cytomegalovirus genomes by type I interferon governs virus latency PLoS pathog. 10 2014 e1003962
47. J. Sewatanon, H. Liu, and P.D. Ling Promyelocytic leukemia protein modulates establishment and maintenance of latent gammaherpesvirus infection in peritoneal cells J. Virol. 87 2013 12151 12157
48. M. Lusic, B. Marini, H. Ali, B. Lucic, R. Luzzati, and M. Giacca Proximity to PML nuclear bodies regulates HIV-1 latency in CD4+ T cells Cell Host Microbe. 13 2013 665 677
49. W.H. Feng, G. Hong, H.J. Delecluse, and S.C. Kenney Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas J. Virol. 78 2004 1893 1902
50. M. Daibata, K. Bandobashi, M. Kuroda, S. Imai, I. Miyoshi, and H. Taguchi Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo J. Virol. 79 2005 5875 5879